🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are increasing around the world, with data suggesting more than 82 million instances annually. Particularly high rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the reality of growing infection rates, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This approval marks a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Results and Worldwide Availability

As per findings published in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which involves two antibiotics. The research involved nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Doctors on the front lines have shared positive views. Access to a easy-to-administer therapy such as this is described as a "game-changer" for public health efforts. This is deemed crucial to alleviate the strain of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.